DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1866)

Type 1 Diabetes | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms, Claims Data Analysis (US)

Type 1 Diabetes | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms, Claims Data Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins and Symlin, with Lantus as the patient-share leader in the United States. Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated T1D. However, differences exist in choice of branded insulin, choice of regimen, and order in which brands and/or regimens are attempted. In addition, the launch of biosimilar insulins is having a profound effect on the T1D therapy market, and we are witnessing mixed physician attitudes toward this new treatment option.

QUESTIONS ANSWERED

  • What patient shares do Lantus, NovoLog, and Levemir garner by line of therapy in newly diagnosed type 1 diabetes patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed type 1 diabetes patients?
  • What percentage of type 1 diabetes patients receive insulin within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of type 1 diabetes patients are treated with monotherapy vs. combination therapy insulin? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated type 1 diabetes patients?

CONTENT HIGHLIGHTS

Geographies: United States

Real World Data: Longitudinal patient-level claims data analysis

Key Drugs Covered: Lantus, Levemir, Toujeo, Apidra, NovoLog, Fiasp, Humalog, Tresiba, Admelog, Basaglar

Key analysis provided:

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms, Claims Data Analysis (US)
    • Treatment Algorithms Claims Data Analysis Type 1 Diabetes US February 2019

Already a Client? Log in to access this report.

  • Pub Date: January 2019
  • Author(s): Kerri Brown, M Pharm
  • Kerri Brown, is an analyst with Decision Resources Group, focused on finding stories in data and developing products to inform strategic decisions in the hemophilia and diabetes spaces. Kerri holds a master of pharmacy degree from King’s College London with 1 st class honors. Prior to joining DRG, she was a national clinical educator at a UK diabetes start-up, and has extensive experience of diabetes medical devices. Kerri has worked at AstraZeneca, and as a pharmacist in a national psychiatric clinical trial center. In addition to her work at DRG, Kerri is a practicing pharmacist with extensive clinical experience of UK physician prescribing in diabetes.

Purchase Report

Recent reports:
You may also be interested in: